Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
Clinical Pharmacology and Therapeutics
|
April 19, 2017
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
D M Longo, G T Generaux, B A Howell, et al.
Pharmacogenetics
|
December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
Y S Lin, G F Lockwood, M A Graham, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 4, 1999
Molecular and physical mechanisms of first-pass extraction
S D Hall, K E Thummel, P B Watkins, et al.
Clinical and Experimental Immunology
|
November 25, 2014
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
D M Foureau, T L Walling, V Maddukuri, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 7, 2007
Blood gene expression signatures predict exposure levels
P R Bushel, A N Heinloth, J Li, et al.
Nature Genetics
|
March 30, 2001
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, et al.
Pharmacogenetics
|
October 23, 2001
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, E D Green, et al.
Pharmacological Reviews
|
June 1, 2004
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5
E G Schuetz, M V Relling, S Kishi, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
Clinical Pharmacology and Therapeutics
|
April 19, 2017
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
D M Longo, G T Generaux, B A Howell, et al.
Pharmacogenetics
|
December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
Y S Lin, G F Lockwood, M A Graham, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 4, 1999
Molecular and physical mechanisms of first-pass extraction
S D Hall, K E Thummel, P B Watkins, et al.
Clinical and Experimental Immunology
|
November 25, 2014
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
D M Foureau, T L Walling, V Maddukuri, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 7, 2007
Blood gene expression signatures predict exposure levels
P R Bushel, A N Heinloth, J Li, et al.
Nature Genetics
|
March 30, 2001
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, et al.
Pharmacogenetics
|
October 23, 2001
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, E D Green, et al.
Pharmacological Reviews
|
June 1, 2004
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5
E G Schuetz, M V Relling, S Kishi, et al.
Page
of 10